In short
This article discusses a clinical trial investigating the use of 68Ga-Nota-Abscint-Her2, a radiodiagnostic agent, in PET/CT imaging for patients with metastatic breast cancer. The study aims to evaluate the diagnostic performance of this novel imaging technique in detecting HER2 expression and its potential impact on treatment decisions for patients with various subtypes of metastatic breast cancer.
At a glance
- Study Type
- Phase II, interventional, prospective, single-arm radio-diagnostic study
- Primary Objective
- Evaluate diagnostic performance of 68Ga-ABS011 PET/CT compared to standard HER2 status tests
- Key Eligibility Criteria
- Adults with metastatic breast cancer (hormone receptor-positive/HER2-negative, triple-negative, or HER2-positive)
- Main Procedures
- 68Ga-ABS011 PET/CT, 18F-FDG PET/CT, tumor biopsies, IHC/ISH analyses
- Primary Endpoint
- Diagnostic agreement between 68Ga-ABS011 PET/CT and IHC/ISH HER2 status
- Secondary Objectives
- Safety assessment, impact on treatment management, evaluation of tumor heterogeneity
- Potential Impact
- Improved whole-body mapping of HER2 expression, potential to guide personalized treatment decisions
What is 68Ga-NOTA-ABSCINT-HER2?
68Ga-NOTA-ABSCINT-HER2, also known as 68Ga-ABS011, is a new diagnostic tool being studied for patients with metastatic breast cancer (mBC). It is a radiodiagnostic agent, which means it's a substance that can be used to create images of the inside of your body to help doctors diagnose or monitor certain conditions.
Purpose of the Study
The main goal of this study is to evaluate how well 68Ga-ABS011 performs in diagnosing HER2 status in patients with metastatic breast cancer. HER2 (Human Epidermal Growth Factor Receptor 2) is a protein that promotes the growth of cancer cells. Some breast cancers have higher levels of HER2, which can affect treatment decisions.
How Does It Work?
68Ga-ABS011 is used in a special type of imaging test called PET/CT (Positron Emission Tomography/Computed Tomography). This test combines two different imaging techniques to create detailed pictures of the inside of your body. The 68Ga-ABS011 is injected into your body and attaches to HER2 proteins on cancer cells. This allows doctors to see where in your body the cancer has spread and whether these cancer cells have high levels of HER2.
Potential Benefits
The use of 68Ga-ABS011 PET/CT may offer several potential benefits:
- It could provide a more accurate picture of HER2 status across the entire body, which is important because HER2 levels can vary between different tumor sites.
- It might help doctors make better decisions about treatment, especially regarding the use of HER2-targeted therapies.
- It could potentially reduce the need for multiple biopsies, which can be invasive and uncomfortable.
Who Can Participate?
This study is designed for adult patients with metastatic breast cancer. Specifically, it includes patients with:
- Hormone receptor-positive/HER2-negative mBC: This means the cancer grows in response to hormones but doesn't have high levels of HER2.
- Triple-negative mBC: This type of breast cancer doesn't have high levels of estrogen receptors, progesterone receptors, or HER2.
- HER2-positive mBC: This type has high levels of HER2.
Participants must be at least 18 years old and have at least one tumor that can be biopsied and is visible on another type of scan called FDG PET/CT.
Study Procedure
The study involves two main phases:
- Diagnostic phase: Participants will undergo several tests, including:
- A standard FDG PET/CT scan
- A biopsy guided by the FDG PET/CT scan
- The new 68Ga-ABS011 PET/CT scan
- A second biopsy guided by the 68Ga-ABS011 scan (this is optional for some patients)
- Treatment follow-up phase: If the tests show that a patient might benefit from HER2-targeted therapy, they will receive this treatment and have another FDG PET/CT scan after 6 weeks.
Safety Considerations
As with any medical procedure, there are some safety considerations:
- The study will monitor for any side effects or reactions to 68Ga-ABS011.
- Patients with certain conditions, such as severely impaired kidney function or liver problems, may not be able to participate.
- Pregnant or breastfeeding women cannot participate in the study.
It's important to discuss any concerns or questions with your doctor before deciding to participate in this study.